N/A N=200 Provision of HIV Self-Test Kit to Emergency Department Patients
HIV Infections
Primary: Number of Participants Who Did HIV Testing — 36; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
Osteoporosis
Primary: Change From Baseline in Bone Mineral Density (BMD) Measured by Dual-Energy X-ray Absorptiometry (DXA) — -0.0026; 0.1299; 0.1196; -0.0029 gram per centimeter squared…
Phase 1 N=11 Administration of IV Laronidase Post Bone Marrow Transplant in Hurler
Hurler Syndrome
Primary: Percentage of Adherence to the Scheduled Weekly Infusion by the Participants — 99 percentage
Phase 2 N=136 Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Advanced Solid Tumors
Primary: Determination of Recommended Phase 2 Dose (RP2D) of BVD-523 by Dose-limiting Toxicities (DLT). — 0; 0; 0; 0 Participants
N/A N=18 The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women
Endothelial Dysfunction
Primary: Percent Change in Brachial Artery Flow-mediated Dilation at Each Time Point — 4.11; 6.93; 5.86; 3.20 Percent Change
Phase 1 N=20 Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
HCV Infection
Primary: Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast — 662.7; 383.3 h*ng/mL
Phase 1 N=99 A Study Comparing User Experience of Different Delivery Devices for Glucagon
Healthy
Primary: Percentage of Trained Users That Performed a Successful Administration for Each Device — 90.3; 15.6 percentage of participants — p=<.0001
Phase 2 N=254 Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
Psoriasis · Psoriatic Arthritis · Psoriasis Arthropatica
Primary: Percentage of Participants Who Achieved a 75% Improvement (Response) From Baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 16 — 7.1; 23.5; 28.2…
N/A N=42 Helping Moms to be Healthy After Baby
Weight Loss · Diet Modification · Obesity
Primary: Feasibility of Recruitment — 22; 19 participants
N/A N=200 Determinants of Smoking Cessation Among Latinos
Smoking Cessation
Primary: Number of Participants With 24-Hour Smoking Abstinence (Week 3 Post Quit Day) — 100 Participants
Phase 1 N=32 Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Drug Interaction Potential
Primary: Pharmacokinetic Analysis: Maximum Concentration (Cmax) for Midazolam — 13.6; 12.0; 9.7 ng/mL
N/A N=93 Persona TKA With iASSIST Knee System and iASSIST Knee System
Osteoarthritis, Knee
Primary: Number of Participants With Alignment Accuracy of the Knee Femoral Components in Coronal Plain — 39; 36; 3; 5 Participants
Phase 2 N=15 Preoperative Treatment With Cetuximab and/or IMC-A12
Head and Neck Squamous Cell Carcinoma
Primary: AKT Modulation
Phase 2 N=72 Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
Chronic Hepatitis C
Primary: Number of Participants With Sustained Virologic Response — 70 Participants
N/A N=8,565 Evidence-Based Colorectal Cancer Screening for the Uninsured
Colorectal Cancer
Primary: FIT Completion Among Patients Offered Any Incentive vs. Outreach Alone Each Year — 2391; 738; 1255; 394 Participants — p=0.59